Core Viewpoint - The company Valiant Biopharma-B (09887) announced that its drug LBL-034 (a GPRC5D/CD3 bispecific antibody) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM) [1] Group 1 - The drug LBL-034 is specifically designed to target GPRC5D and CD3, indicating a novel therapeutic approach in the treatment of RRMM [1] - The Fast Track Designation by the FDA is aimed at facilitating the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need [1] - This designation may provide the company with advantages such as more frequent communication with the FDA and eligibility for accelerated approval and priority review [1]
维立志博-B：LBL-034(GPRC5D/CD3双特异性T-CELL ENGAGER，TCE)获美国FDA授予快速通道资格认定